Alteration of enzyme expressions in mevalonate pathway - Possible role for cardiovascular remodeling in spontaneously hypertensive rats -

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1409-1417

  Han, Jie ^a   Jiang, Dong Mei ^b   Du, Chang Qing ^a   Hu, Shen Jiang ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Cardiovascular remodeling; Gene expression; Mevalonate pathway; Small GTP binding proteins; Spontaneously hypertensive rats

Indexed keywords

FARNESYLTRANSFERASE ALPHA; FARNESYLTRANSFERASE BETA; GERANYLGERANYL TRANSFERASE I; GERANYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; SQUALENE SYNTHASE; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LOCALIZATION; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HISTOPATHOLOGY; HYPERTENSION; LIPID BLOOD LEVEL; MALE; NONHUMAN; PATHOLOGICAL ANATOMY; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WESTERN BLOTTING;

AGE FACTORS; AGING; ALKYL AND ARYL TRANSFERASES; ANALYSIS OF VARIANCE; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; BLOTTING, WESTERN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FARNESYLTRANSTRANSFERASE; GERANYLTRANSTRANSFERASE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERTENSION; LIVER; MALE; MEVALONIC ACID; MYOCARDIUM; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VENTRICULAR REMODELING;

EID: 79957684772     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1101     Document Type: Article

References (52)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
2. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
3. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem 1992; 267: 20033-20038.
4. Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 2000; 275: 31001-31008.
5. Pravenec M, Kurtz TW. Recent advances in genetics of the spontaneously hypertensive rat. Curr Hypertens Rep 2010; 12: 5-9.
6. Johns DG, Dorrance AM, Leite R, Weber DS, Webb RC. Novel signaling pathways contributing to vascular changes in hypertension. J Biomed Sci 2000; 7: 431-443.
7. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W. Rho family of small G proteins play critical roles in mechanical stressinduced hypertrophic responses in cardiac myocytes. Circ Res 1999; 84: 458-466.
8. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995; 270: 23173-23178.
9. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997; 137: 481-492.
10. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27: 282-293.
11. Lais LT, Rios LL, Boutelle S, DiBona GF, Brody MJ. Arterial pressure development in neonatal and young spontaneously hypertensive rats. Blood Vessels 1977; 14: 277-284.
12. Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 2006; 29: 1756-1758.
13. Kennelly PJ, Rodwell VW. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by reversible phosphorylation-dephosphorylation. J Lipid Res 1985; 26: 903-914.
14. Do R, Kiss RS, Gaudet D, Engert JC. Squalene synthase: A critical enzyme in the cholesterol biosynthesis pathway. Clin Genet 2009; 75: 19-29.
15. Szkopińska A, Plochocka D. Farnesyl diphosphate synthase: Regulation of product specificity. Acta Biochim Pol 2005; 52: 45-55.
16. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem 1996; 271: 5289-5292.
17. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-269.
18. Adams MA, Bobik A, Korner PI. Differential development of vascular and cardiac hypertrophy in genetic hypertension relation to sympathetic function. Hypertension 1989; 14: 191-202.
19. Jin X, Xia L, Wang LS, Shi JZ, Zheng Y, Chen WL. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006; 6: 1948-1956.
20. van Gorp AW, Schenau DS, Hoeks AP, Boudier HA, de Mey JG, Reneman RS. In spontaneously hypertensive rats alterations in aortic wall properties precede development of hypertension. Am J Physiol Heart Circ Physiol 2000; 278: H1241-H1247.
21. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J. Involvement of Rho-kinase in hypertensive vascular disease: A novel therapeutic target in hypertension. FASEB J 2001; 15: 1062-1064.
22. Shirai H, Autieri M, Eguchi S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 2007; 16: 111-115.
23. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002; 106: 2118-2124.
24. Hall A. Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol 1994; 10: 31-54.
25. Aikawa R, Komuro I, Nagai R, Yazaki Y. Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol Cell Biochem 2000; 212: 177-182.
26. Numaguchi K, Eguchi S, Yamakawa T, Motley ED, Inagami T. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments. Circ Res 1999; 85: 5-11.
27. Bagrodia S, Cerione RA. PAK to the future. Trends Cell Biol 1999; 9: 350-355.
28. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341: 1276-1283.
29. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
30. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505-517.
31. Li L, Chen GP, Yang Y, Ye Y, Yao L, Hu SJ. Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. Biochem Pharmacol 2010; 79: 399-406.
32. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27 (Kip1) expression in the vasculature of hypertensive rats. Circ Res 2001; 89: 488-495.
33. Hu WY, Han YJ, Gu LZ, Piano M, de Lanerolle P. Involvement of Ras-regulated myosin light chain phosphorylation in the captopril effects in spontaneously hypertensive rats. Am J Hypertens 2007; 20: 53-61.
34. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
35. Borghi C. Interactions between hypercholesterolemia and hypertension: Implications for therapy. Curr Opin Nephrol Hypertens 2002; 11: 489-496.
36. Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818-826.
37. Rikitake Y, Hirata K. Inhibition of RhoA or Rac1? Mechanism of cholesterol-independent beneficial effects of statins. Circ J 2009; 73: 231-232.
38. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361-370.
39. Lever AF, Harrap SB. Essential hypertension: A disorder of growth with origins in childhood? J Hypertens 1992; 10: 101-120.
40. Mulvany MJ. The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol 1992; 19: S22-S27.
41. Korner PI, Bobik A, Angus JJ. Are cardiac and vascular "amplifiers" both necessary for the development of hypertension? Kidney Int Suppl 1992; 37: S38-S44.
42. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999; 84: 1186-1193.
43. Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem 2000; 128: 719-722.
44. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001; 38: 100-104.
45. Numaguchi K, Eguchi S, Yamakawa T, Motley ED, Inagami T. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments. Circ Res 1999; 85: 5-11.
46. Li S, Chen BP, Azuma N, Hu YL, Wu SZ, Sumpio BE, et al. Distinct roles for the small GTPases Cdc42 and Rho in endothelial responses to shear stress. J Clin Invest 1999; 103: 1141-1150.
47. Gould RG. Lipid metabolism and atherosclerosis. Am J Med 1951; 11: 209-227.
48. Iritani N, Fukuda E, Nara Y, Yamori Y. Lipid metabolism in spontaneously hypertensive rats (SHR). Atherosclerosis 1977; 28: 217-222.
49. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: Possible involvement in neural mechanisms of hypertension. Circ Res 92: 1337-1343.
50. Jackson EK, Andresen BT, Seasholtz TM, Zhu C, Romero GG. Enhanced activation of RhoA by angiotensin II in SHR preglomerular microvascular smooth muscle cells. J Cardiovasc Pharmacol 2005; 45: 283-285.
51. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 2006; 27: 97-104.
52. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. J Hypertens 2008; 26: 1837-1848.